Autoimmune manifestations associated with myelodysplastic syndromes

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Autoimmune disorders (ADs) are a significant comorbidity in myelodysplastic syndromes (MDS), affecting 10-20% of patients.
• ADs are more prevalent in younger MDS patients with higher International Prognostic Scoring System (IPSS) scores.
• Commonly associated MDS subtypes include MDS with single lineage dysplasia (MDS-SLD) and MDS with excess blasts (MDS-EB).

Purpose of the Study:

• To review the spectrum of autoimmune disorders associated with myelodysplastic syndromes.
• To discuss the impact of ADs on MDS prognosis and treatment strategies.
• To explore the potential of MDS-specific therapies in managing autoimmune complications.

Main Methods:

• Review of existing literature and clinical data on autoimmune disorders in MDS patients.
• Analysis of patient demographics, MDS subtypes, and associated autoimmune conditions.
• Evaluation of treatment outcomes for ADs in the context of MDS management.

Main Results:

• A wide range of ADs, from localized to systemic, are observed in MDS patients.
• Frequently reported ADs include vasculitis, connective tissue diseases, inflammatory arthritis, and neutrophilic diseases.
• ADs generally do not worsen MDS survival, but some, like vasculitis, may indicate adverse outcomes or disease progression (e.g., Sweet syndrome).

Conclusions:

• While steroids and immunosuppressive treatment (IST) are standard first-line therapies for ADs in MDS, their use can be limited.
• MDS-specific therapies, such as hypomethylating agents, demonstrate immunomodulatory effects beneficial for treating ADs.
• These agents may offer an effective alternative for managing autoimmune complications, potentially reducing reliance on steroids.